NCT05732961View on ClinicalTrials.gov

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

PHASE2SuspendedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

June 20, 2026

Study Completion Date

September 30, 2026

Conditions
Myelodysplastic SyndromesMyeloproliferative NeoplasmAnemia
Interventions
DRUG

Luspatercept

Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05732961 - Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | Biotech Hunter | Biotech Hunter